The National Institute for Health and Care Excellence (NICE) has updated its guidance on Heavy Menstrual Bleeding: assessment and management.
This guideline (NG88) covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.
In this update, published in November 2018, NICE reinstated recommendations on ulipristal acetate (Esmya) following the European Medicines Agency review of the use of Esmya for uterine fibroids. NICE also added information on shared decision making and monitoring for side effects.